Macrogenics And Sagard Healthcare Partners Enter Into Expanded Zynyz® Royalty Purchase Agreement
View all comments(0)
May 4 (Reuters) - MacroGenics Inc MGNX.O:
MACROGENICS AND SAGARD HEALTHCARE PARTNERS ENTER INTO EXPANDED ZYNYZ® ROYALTY PURCHASE AGREEMENT
MACROGENICS INC - RECEIVES $60 MILLION UPFRONT, ELIGIBLE FOR UP TO $20 MILLION 2026 MILESTONE
MACROGENICS INC - ALL ROYALTY RIGHTS REVERT TO MACROGENICS AFTER SAGARD RECEIVES 1.7X OR 2.0X INVESTMENT BY SEPTEMBER 30, 2032
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.